|Delayed - 11/24 04:10:00 pm|
Eli Lilly and : US to receive 300,000 vials of experimental COVID-19 antibody therapy
|10/29/2020 | 11:31am|
According to Lilly, under the terms of the agreement the vials will be accepted if the
The company said that it is partnering globally with governments and philanthropic organisations to allocate the limited supply of antibody therapies.
“Lilly has leveraged our deep scientific capability to fight this pandemic, and we are proud of our efforts to develop potential medicines to combat COVID-19. Supply agreements with governments - such as this one with the US… - are fundamental to enable the most widespread and equitable access to our potential therapy,” said
The company added that it has been investing in large-scale manufacturing and anticipates producing up to one million doses of bamlanivimab 700 mg by the end of 2020, with 100,000 doses ready to ship globally after authorisation. It also expects to continue to bring more manufacturing resources online throughout the year and therefore significantly increase supply in the first quarter of 2021.
US enters agreement for experimental prophylactic COVID-19 antibody cocktail…
The post US to receive 300,000 vials of experimental COVID-19 antibody therapy appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2020. All Rights Reserved., source